Perrigo Sues FDA For Failing To Publish Approval Of Gel

By Brian Mahoney (March 24, 2014, 2:20 PM EDT) -- Perrigo Israel Pharmaceuticals Ltd. on Friday sued the U.S. Food and Drug Administration in D.C. federal court, alleging the agency has failed to update its records to reflect its approval of Perrigo's testosterone gel product.

The company sued to redress the agency's alleged failure to timely update its so-called Approved Drug Products with Therapeutic Equivalence Evaluations — also known as the Orange Book — to add a therapeutic equivalence rating for the testosterone gel, which is a generic version of AbbVie's AndroGel.

The alleged failure "continues to cause actual and imminent harm to Perrigo," the complaint said.

The FDA approved the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!